• S Bazarbashi, M A Raja, A El Sayed, A Ezzat, E Ibrahim, S Kattan, A Kardar, A Peracha, E Lindstedt, and K Hanash.
• Department of Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. bazarbashi@kfshrc.edu.sa
• J Surg Oncol. 2000 Jul 1; 74 (3): 181-4.

Background And ObjectiveEvaluate the efficacy and toxicity of alternating intravesical instillation of Bacillus Calmette-Guerin(BCG) and Interferon alpha2-b (IFN) in the treatment and prevention of recurrence of superficial transitional cell carcinoma (TCC) of the urinary bladder.MethodsPatients with Ta, T1 tumors and carcinoma in situ, either recurrent (TaG1, T1G1) or primary/recurrent TaG2 TaG3, T1G2, T1G3 and Tis (T: Tumor stage, G: grade) are eligible. All patients received intravesical BCG 81 mg on Weeks 1, 3, 5 and 7 and IFN 100 million units on Weeks 2, 4, 6 and 8. Cystoscopy performed 4 weeks after completion of therapy, and every 3 months thereafter.ResultsThere was a total of 37 patients. Thirteen had TaG2, 13 T1G2, 1 T1G1, 4 TaG1, 1 TaG3, 3 T1G3 and 7 Tis (5 concurrent with other above tumors). Index lesion cleared in 7/10 patients. With a median follow-up of 26.2 month, 22 patients (59%) failed above therapy. Median time to treatment failure was 7 months. Seven, 6 and 9 patients recurred at a higher, lower and same stage or grade respectively. No grade 3 or 4 toxicity was encountered.ConclusionsAlternating intravesical BCG and IFN is effective and well tolerated therapy for superficial TCC of urinary bladder.

33 keywords...

hide…